Contribute Try STAT+ Today

finance

Most Read

Moderna sign

Exclusive By Damian Garde

Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine

Bristol Myers Squibb sign

Pharmalot By Ed Silverman

Former Celgene shareholders claim Bristol Myers reaped a $6.4 billion windfall by delaying a drug approval

Pittsburgh CVS

Health Tech By Erin Brodwin

How CVS is tapping into its consumer expertise in a new venture fund

coronavirus/toilet paper

First Opinion By Darren Schulte

The novel coronavirus is a serious threat. We need to prepare, not overreact

Lab coats

First Opinion By Zach Nayer

How much do doctors really make? Compare your salary to various specialties

money in syringe vaccine

Pharma By Olivia Goldhill

Behind the scenes, companies helping big Covid-19 vaccine makers are getting rich

Early vaccination -moms and kids

First Opinion By Stewart Lyman

Pharma’s tarnished reputation helps fuel the anti-vaccine movement

handing doc money

Business By Alicia Diaz

Medical device firms’ payments to doctors far outstripped those from pharma, study shows

All Coverage

Cash on yellow background

Pharmalot By Ed Silverman

Planned changes at Soros’ Open Society has access-to-medicines advocacy groups on edge

Biotech By Damian Garde and Hyacinth Empinado

Watch: SPACs are all the rage, but what are they? STAT explains

advertisement

Regeneron

Pharmalot By Ed Silverman

Regeneron shareholders urged to boot board member over executive pay practices

One Medical

Health Tech By Katie Palmer

One Medical eyes the full lifespan with acquisition of Medicare-focused Iora Health

Unicorn Money

Biotech By Kate Sheridan

Will you accept this capital investment? Biotech and health startups bet on a strange new reality show for crowdfunding

Follow the money: What’s next in health tech

Health Tech By Damian Garde

There’s a gold rush in health tech. Here’s how the smart money stays ahead

Ginkgo Bioworks 05

Biotech By Jonathan Saltzman and Anissa Gardizy — Boston Globe

Ginkgo plans a $17.5 billion merger with SPAC that took DraftKings public

Rising Drug Cost

Pharmalot By Ed Silverman

Global spending on medicines could hit $1.6 trillion by 2025 — and that doesn’t include Covid-19 vaccines

pill shopping cart

Opinions+ By Peter Bak

Investment in antimicrobials was up in 2020, but much work remains

Microbiome illo

Biotech By Kate Sheridan

The field is exploding, but microbiome therapeutics still face a wave of challenges

patient equation patient friction coefficient

First Opinion By Travis Whitfill

To create value, pharma companies should prioritize innovation, not shareholders

telehealth concept photo illo

Health Tech By Mario Aguilar

Accolade to acquire PlushCare as telehealth competition intensifies

Cash on yellow background

Biotech By Anissa Gardizy — Boston Globe

Adagio raises $336 million to advance Covid-19 antibody treatment

Human Colon Cancer Cells

Biotech By Anissa Gardizy — Boston Globe

Tango Therapeutics to go public in $353 million SPAC deal

money pile

Biotech By Kate Sheridan

Biotech venture capitalists have more money than ever to invest. What could possibly go wrong?

Bribery

Pharmalot By Ed Silverman

Lilly is a holdout among companies that agree to disclose when executive pay is clawed back

telehealth concept photo illo

Health Tech By STAT staff

The health tech tracker for the second quarter: 15 pivotal industry events to watch

Green and purple bacteria

Biotech By Kate Sheridan

Microbiome company Finch Therapeutics begins trading publicly, quietly shuffles one of its executives

SPAC storm

Health Tech By Casey Ross

How the wave of telehealth SPACs during the pandemic could create a ‘perfect storm’ for investors

AmerisourceBergen

Pharmalot By Ed Silverman

AmerisourceBergen say-on-pay proposal squeaks by amid outrage over CEO compensation

stethoscope & tablet on table

Exclusive By Erin Brodwin

VC firm General Catalyst taps expertise of former Ancestry, Livongo, and Gilead executives

Pills and money illustration

The Pharmalot View By Ed Silverman

‘Deeply problematic’: AmerisourceBergen rewards its CEO despite the ravages of the opioid crisis

Stethoscope & tablet digital therapeutics

Health Tech By Erin Brodwin

Cigna’s Evernorth to acquire telehealth company MDLive

Medical costs

Pharmalot By Ed Silverman

Once again, the credit outlook for the pharmaceutical industry is negative

antibiotics/teal background

Pharmalot By Ed Silverman

Pharma’s ambitious new antibiotic venture hires a CEO to fix a ‘broken’ pipeline